DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
566,Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A,"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial",CARDIOVASC.DIABETOL,2017,16,1.0,1~10,,DAPA-HDL,NCT02327039,T2D,Parallel,IT,Phase 4,0.0,Single-Blind,True,placebo,Placebo,0,MG,ORAL,QAM,TAB,33,16.0,16,,CO,Student T Test,,0.0,WK,HbA1c,Mean,8.2,percent,0.2,SE,,,Mean,0.0,percent,,,,,Mean,8.2,percent,0.2,SE,,,Mean,0.0,,,,,66.7,61.0,YR
566,Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A,"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial",CARDIOVASC.DIABETOL,2017,16,1.0,1~10,,DAPA-HDL,NCT02327039,T2D,Parallel,IT,Phase 4,0.0,Single-Blind,True,placebo,Placebo,0,MG,ORAL,QAM,TAB,33,16.0,16,,CO,Student T Test,,12.0,WK,HbA1c,Mean,8.2,percent,0.2,SE,,,Mean,0.4,percent,0.2,SE,-0.024,0.824,Mean,8.6,percent,0.4,SE,7.752,9.448,Mean,4.878,,,,,66.7,61.0,YR
566,Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A,"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial",CARDIOVASC.DIABETOL,2017,16,1.0,1~10,,DAPA-HDL,NCT02327039,T2D,Parallel,IT,Phase 4,1.0,Single-Blind,True,dapagliflozin,SGLT2,10,MG,ORAL,QAM,TAB,33,17.0,17,,CO,Student T Test,,0.0,WK,HbA1c,Mean,8.2,percent,0.2,SE,,,Mean,0.0,percent,,,,,Mean,8.2,percent,0.2,SE,,,Mean,0.0,,,,,68.8,66.3,YR
566,Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A,"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial",CARDIOVASC.DIABETOL,2017,16,1.0,1~10,,DAPA-HDL,NCT02327039,T2D,Parallel,IT,Phase 4,1.0,Single-Blind,True,dapagliflozin,SGLT2,10,MG,ORAL,QAM,TAB,33,17.0,17,,CO,Student T Test,,12.0,WK,HbA1c,Mean,8.2,percent,0.2,SE,,,Mean,-0.9,percent,0.2,SE,-1.322,-0.478,Mean,7.3,percent,0.4,SE,6.456,8.144,Mean,-10.976,,,,,68.8,66.3,YR
